Table 3.
Treatment and Outcomes Associated With AF/AFL
| All Patients (N = 3,970) | No AF/AFL (n = 3,595) | All AF/AFL (n = 375) | p Value | New-Onset AF/AFL | p Value | |
|---|---|---|---|---|---|---|
| Hospital treatments | ||||||
| Hydroxychloroquine | 2,970 (75) | 2,714 (76) | 256 (68) | <0.01 | 113 (77) | 0.60 |
| Azithromycin | 2,726 (69) | 2,479 (69) | 247 (66) | 0.22 | 105 (72) | 0.45 |
| Remdesivir | 59 (2) | 49 (1) | 10 (3) | 0.07 | 6 (4) | 0.01 |
| Interleukin-6 directed drugs | 248 (6) | 220 (6) | 28 (8) | 0.32 | 19 (13) | <0.01 |
| Tocilizumab | 211 (5) | 189 (5) | 22 (6) | 15 (10) | 0.01 | |
| Sarilumab | 37 (1) | 31 (1) | 6 (2) | 4 (3) | 0.02 | |
| Antiarrhythmic drugs | 182 (5) | 87 (3) | 95 (25) | <0.01 | 51 (35) | <0.01 |
| Amiodarone | 164 (4) | 78 (2) | 86 (23) | <0.01 | 50 (34) | <0.01 |
| Therapeutic anticoagulation | 1,587 (40) | 1,319 (37) | 268 (72) | <0.01 | 114 (78) | <0.01 |
| Prophylactic anticoagulation | 3,150 (79) | 2,948 (82) | 202 (54) | <0.01 | 105 (72) | <0.01 |
| Steroids | 1,173 (30) | 1,022 (28) | 151 (40) | <0.01 | 68 (47) | <0.01 |
| Intubation | 650 (16) | 550 (15) | 100 (27) | <0.01 | 55 (38) | <0.01 |
| Number of vasopressors | 0.21 ± 0.61 | 0.20 ± 0.60 | 0.35 ± 0.78 | <0.01 | 0.51 ± 0.85 | <0.01 |
| Outcomes | ||||||
| Ischemic stroke or TIA | 29 (1) | 23 (1) | 6 (2) | 0.05 | 4 (3) | <0.01 |
| Hemorrhagic stroke | 5 (0.1) | 5 (0.1) | 0 (0.0) | 0.47 | 0(0.0) | 0.65 |
| Death | 1,104 (28) | 933 (26) | 171 (46) | <0.01 | 80 (55) | <0.01 |
| Hospital length of stay, days | 7 (4–11) | 7 (3–11) | 8 (4–13) | <0.01 | 9 (5-17) | 0.09 |
Values are n (%), mean ± SD, or median (interquartile range). Bold values indicates p ≤ 0.05.
Abbreviations as in Table 1.